Lenacapavir prevents production of infectious HIV-1 by abrogating immature virus assembly.

This study reveals that Lenacapavir prevents infectious HIV-1 production by inducing a "premature" capsid lattice during viral assembly that mimics the mature state despite lacking inositol hexakisphosphate, thereby disrupting the normal formation of infectious virions.

The Gist

The Big Picture: Stopping a Virus in Its Tracks

Imagine HIV-1 as a tiny, sophisticated factory that builds its own escape vehicles (viruses) to infect new cells. To work, this factory needs to build a specific "shell" (called the Capsid) around its genetic instructions. This shell has to be built in two stages:

1. The Rough Draft (Immature): A messy, hexagonal honeycomb structure.
2. The Final Product (Mature): A sleek, cone-shaped helmet that protects the virus's DNA.

The drug Lenacapavir (brand names Sunlenca and Yeztugo) is a new weapon against HIV. We already knew it could jam the virus's engine after it was built, preventing it from entering a new cell. But this paper asks a new question: What happens if Lenacapavir attacks the factory while the virus is being built?

The answer is surprising: It doesn't just jam the engine; it causes the factory to build a completely broken, unusable vehicle.

---

The Analogy: The "Premature" Construction Site

Think of the HIV virus assembly line like a construction crew building a dome.

1. The Normal Process (Without the Drug)

• The Blueprint: The crew needs a special glue called IP6 (a natural molecule found in our cells) to hold the bricks together.
• The Steps: They build a rough, flat honeycomb (Immature). Then, a "foreman" (a viral enzyme called Protease) cuts the scaffolding away. This allows the honeycomb to snap into a perfect, curved dome (Mature).
• The Result: A sturdy, curved dome that can travel and infect.

2. The Drug's Attack (Lenacapavir)
Lenacapavir is like a super-strong, sticky tape that gets stuck in the wrong place on the bricks.

• The "Glue" Problem: The construction crew tries to use their special glue (IP6), but the sticky tape (Lenacapavir) blocks the glue from working.
• The "Premature" Mistake: Because the glue isn't there, the crew gets confused. Instead of building the rough honeycomb first, the drug tricks them into building a flat, rigid, "mature-looking" structure right from the start.
• The Name: The scientists call this a "Premature Lattice." It's like trying to wear a finished suit of armor while you are still in the womb. It looks like armor, but it's built on the wrong foundation.

What Went Wrong? (The Structural Damage)

Using a powerful microscope (Cryo-EM), the scientists took 3D pictures of these broken viruses. Here is what they found:

• The Shape is Wrong: Instead of a nice curved dome, the virus particles are huge, flat, and floppy. They are like a deflated beach ball instead of a bouncy ball.
• Missing Pieces: A real virus needs 12 special "pentagon" bricks to close the dome into a cone. Because the drug messed up the assembly, these pentagons never formed. The dome can't close.
• No Glue: The special glue (IP6) is completely missing from these broken structures. Without it, the virus is unstable.

The "Insoluble" Pile-Up

The researchers also looked inside the infected cells.

• Normal: The virus parts are like loose sand, easy to move and assemble.
• With Drug: The virus parts clump together into giant, solid rocks (aggregates) that the cell can't move.
• The Twist: The drug didn't stop the factory from making the bricks (the virus proteins). It just made the bricks turn into a giant, insoluble pile of concrete that couldn't be assembled correctly.

The Final Result: A Dead-End Virus

When these "Premature" viruses are released from the factory:

1. They are too big and flat to move properly.
2. They lack the curved shape needed to protect their DNA.
3. Even if they somehow get into a new cell, the "armor" falls apart immediately because it was built wrong.
4. The virus's genetic code is exposed and destroyed before it can do any damage.

Why This Matters

This paper solves a mystery. We knew Lenacapavir worked, but we didn't know how it stopped the virus from being born.

• Old Idea: It just stops the virus from entering the nucleus later.
• New Discovery: It actually sabotages the construction site. It forces the virus to build a "fake" version of itself that looks mature but is structurally doomed.

The Takeaway: Lenacapavir is a double-agent. It doesn't just lock the front door; it walks into the factory, kicks over the scaffolding, and forces the workers to build a house that has no roof and no foundation. The virus tries to leave, but it collapses before it even hits the street.

Technical Summary

1. Problem Statement

Lenacapavir (LEN) is a first-in-class, FDA-approved HIV-1 capsid (CA) inhibitor that disrupts both early (reverse transcription, nuclear entry) and late (assembly, maturation) stages of the viral lifecycle. While its mechanism of blocking nuclear entry by binding to the FG-pocket of mature CA hexamers is well-characterized, its specific effects on immature virus assembly and maturation remain unclear. Specifically, it is unknown how LEN interacts with the Gag polyprotein during the assembly phase (prior to protease cleavage) and whether it alters the structural pathway from the immature Gag lattice to the mature capsid. Understanding these mechanisms is critical for overcoming resistance and designing second-generation inhibitors.

2. Methodology

The authors employed a multi-faceted approach combining structural biology, virology, and cell biology:

• Cryo-Electron Microscopy (Cryo-EM) & Single Particle Analysis (SPA):
  • In Vitro: Assembled Virus-Like Particles (VLPs) using a purified HIV-1 Gag construct (CASPNC) in the presence and absence of LEN and varying concentrations of Inositol Hexakisphosphate (IP6).
  • In Situ: Produced authentic immature VLPs from 293FT cells using a protease-defective (PR-D25A) HIV-1 provirus to trap the lattice in an immature state. Cells were pretreated with LEN.
  • Controls: Included wild-type (PR-WT) mature VLPs and resistance-associated mutation (RAM) variants (M66I).
• Structural Modeling: Used molecular dynamics flexible fitting (MDFF) and force-field parameterization (QM-derived CHARMM parameters) to model LEN binding and hydration states within the cryo-EM maps.
• Infectivity Assays: Measured viral infectivity using flow cytometry (GFP reporter) and quantitative PCR (qPCR) to track reverse transcription (RT) products (early, intermediate, late, and 2LTR circles).
• Biochemical & Cellular Analysis:
  • Western Blot: Quantified Gag expression and release.
  • Confocal Microscopy: Visualized Gag localization (Gag-mNeonGreen fusion) to assess solubility and aggregation.
  • IPPK-KO Cells: Used cells lacking inositol polyphosphate multikinase (IPPK) to deplete cellular IP6 and test LEN's dependency on IP6.

3. Key Contributions

• Discovery of a "Premature" Lattice: The study identifies a novel, aberrant structural state termed the "premature" lattice. This state exhibits a mature-like CA hexameric arrangement despite the absence of protease cleavage (Gag remains uncleaved).
• Mechanism of Assembly Disruption: The authors demonstrate that LEN does not merely inhibit assembly but actively remodels the immature Gag lattice. It forces the CA domain into a mature conformation prior to protease cleavage, bypassing the normal IP6-dependent assembly pathway.
• Structural Resolution of Resistance: The paper presents the first cryo-EM structure of LEN bound to a resistance-associated mutation (M66I) within an immature lattice, revealing how rotational freedom of the drug molecule contributes to resistance.
• IP6 Displacement: The study reveals that the LEN-induced premature lattice lacks the central IP6 density typically required for both immature and mature hexamer stability, explaining the failure to form proper pentamers and close the capsid.

4. Key Results

• Structural Remodeling (In Vitro vs. In Situ):
  • In Vitro: LEN binding to purified CASPNC caused a ~14° rotation of the N-terminal domain (NTD) around the three-fold axis (αH2), but the lattice largely retained immature morphology unless IP6 was low.
  • In Situ: In cells, LEN treatment caused a dramatic shift. At 50 nM LEN, VLPs formed a flat, mature-like hexameric lattice without protease cleavage. These particles were enlarged (100–500 nm) and lacked the curvature required for normal budding.
• The "Premature" State:
  • The premature lattice (PR-D25A + LEN) showed minimal structural deviation from the mature lattice (RMSD 0.985 Å) but retained the Gag membrane tether (no MA-CA cleavage).
  • Crucially, IP6 density was absent in the premature lattice, whereas it is essential for normal immature and mature assembly.
  • Pentamer Absence: The premature lattice consisted almost exclusively of hexamers; no pentamers were observed. Since pentamers are required to close the capsid cone, this leads to unstable, non-infectious particles.
• Resistance Mechanism (M66I):
  • The M66I mutation (which confers high-level resistance) allows the M3a moiety of LEN to rotate freely, preventing the steric clash that normally stabilizes the drug in the wild-type lattice.
• Infectivity and Reverse Transcription:
  • Virus produced from LEN-treated producer cells showed a dose-dependent loss of infectivity.
  • qPCR revealed a severe reduction in RT products (early to late transcripts) in target cells, indicating that the defective capsids fail to protect the viral genome or facilitate reverse transcription.
  • Solubility vs. Expression: LEN did not reduce total Gag protein expression (confirmed by urea lysis) but caused Gag to aggregate into insoluble aggresomes (RIPA-insoluble), reducing the pool of soluble Gag available for proper assembly.
• Dual Blockade:
  • Assembly Block: LEN prevents the formation of a closed, infectious capsid by forcing a premature, flat, IP6-deficient lattice.
  • Entry Block: Any rare particles that escape this defect still carry LEN, which blocks nuclear entry by occupying the FG-pocket.

5. Significance

• Novel Mechanism of Action: This paper redefines LEN's mechanism in the late stage of the lifecycle. It is not just a "capsid stabilizer" but a "lattice remodeler" that hijacks the assembly process to create non-functional, premature particles.
• Therapeutic Implications: The findings explain why LEN is effective even at the assembly stage and suggest that the "premature" state is a lethal dead-end for the virus.
• Drug Design: By elucidating the structural basis of the M66I resistance mutation and the hydration changes in the binding pocket, the study provides a blueprint for designing next-generation capsid inhibitors that can overcome current resistance profiles.
• Biological Insight: The work highlights the critical interplay between IP6, Gag conformation, and lattice curvature, demonstrating that LEN effectively decouples the need for IP6 in driving the transition to a mature-like state, albeit a non-functional one.

In conclusion, Lenacapavir prevents infectious HIV-1 production by binding to the nascent immature Gag lattice, forcing it into an aberrant, IP6-deficient, "premature" mature-like conformation that fails to form a closed capsid, thereby blocking reverse transcription and subsequent infection.